Leuko Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Leuko's estimated annual revenue is currently $4M per year.(i)
  • Leuko's estimated revenue per employee is $267,733

Employee Data

  • Leuko has 15 Employees.(i)
  • Leuko grew their employee count by 7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$9.5M323%N/AN/A
#2
$8.3M284%N/AN/A
#3
$4M157%N/AN/A
#4
$4.3M10-29%N/AN/A
#5
$5630M6129-11%$450MN/A
#6
$4M157%N/AN/A
#7
$7.2M5727%$29.6MN/A
#8
$14.1M47-11%N/AN/A
#9
$2.1M157%$44MN/A
#10
$40.9M133-1%N/AN/A
Add Company

Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.

keywords:N/A

N/A

Total Funding

15

Number of Employees

$4M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Leuko's People

NameTitleEmail/Phone
1
Cofounder & CTOReveal Email/Phone
2
Chief Medical OfficerReveal Email/Phone
3
Co-Founder and CEOReveal Email/Phone
4
Hardware EngineerReveal Email/Phone
5
Product Software EngineerReveal Email/Phone
6
Deep Learning EngineeringReveal Email/Phone

Leuko News

2022-04-20 - Judges: Joint winners at INVEST Pitch Perfect's RPM track ...

Another company Leuko, based in Spain, is targeting cancer patients with a device that claims to be the first device for non-invasive white...

2022-04-20 - Judges: Joint winners at INVEST Pitch Perfect's RPM track ...

Another company Leuko, based in Spain, is targeting cancer patients with a device that claims to be the first device for non-invasive white...

2022-03-22 - Trastuzumab deruxtecan shows 'terrific activity' in second line ...

... GlaxoSmithKline, Guardant Health, Leuko, Lilly, Medica Scientia Innovation Research, Menarini, Merck Sharp & Dohme, Nektar Therapeutics,...

2022-03-22 - Trastuzumab deruxtecan shows 'terrific activity' in second line ...

... GlaxoSmithKline, Guardant Health, Leuko, Lilly, Medica Scientia Innovation Research, Menarini, Merck Sharp & Dohme, Nektar Therapeutics,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M15-21%N/A
#2
$1.6M15N/AN/A
#3
$0.6M15-12%$3.7M
#4
$0.5M150%$8.8M
#5
$2.9M15-46%N/A